During gastrulation of the amphibian embryo, specification of the three germ layers, endo-, ecto-, and mesoderm, is regulated by maternal and zygotic mechanisms. Although it is known that mesoderm specification requires the cooperation between TGF-b signaling and p53 activity and requires maternal factors, essential zygotic factors have been elusive. Here, we report that the Zn-finger protein XFDL156 is an ectodermal, zygotic factor that suppresses mesodermal differentiation. XFDL156 overexpression suppresses mesodermal markers, and its depletion induces aberrant mesodermal differentiation in the presumptive ectoderm. Furthermore, we find that XFDL156 and its mammalian homologs interact with the C-terminal regulatory region of p53, thereby inhibiting p53 target gene induction and mesodermal differentiation. Thus, XFDL156 actively restricts mesodermal differentiation in the presumptive ectoderm by controlling the spatiotemporal responsiveness to p53.
INTRODUCTION
During early vertebrate embryogenesis, three germ layers, the ectoderm, mesoderm, and endoderm, are formed from pluripotent cells at the onset of gastrulation. In the Xenopus embryo, germ-layer specification is substantially influenced by maternally deposited positional information. Along the animal-vegetal axis, the ectoderm and endoderm arise from the animal cap and vegetal pole regions, respectively, while the mesoderm forms in the marginal zone (Heasman, 2006) . The early animal cap is pluripotent and the mesoderm is induced in pluripotent cells by endoderm-derived mesodermalizing signals (e.g., Nodal/Xnrs; Schier, 2003) , which are regulated by vegetally localized maternal factors such as VegT (Smith, 1997) . In addition, under the maternal influence, the presumptive mesoderm itself expresses mesoderm-inducing Nodal-related factors, such as Derri ere (Sun et al., 1999) , which reinforce the mesodermal specification (Eimon and Harland, 2002) .
In contrast, it has remained elusive whether the ectodermal specification of pluripotent cells is an active or passive process (Wardle and Smith, 2006) . A recent report on the maternal factor Ectodermin has suggested that it actively prevents presumptive ectodermal cells from undergoing mesodermal differentiation. Ectodermin acts as a RING-type E3 ubiquitin ligase that targets and degrades Smad4, thereby attenuating the responsiveness of animal cap cells to mesoderm-inducing TGF-b-family signals (Dupont et al., 2005) . In addition, previous studies indicated that mesodermal suppression in the animal cap may also involve two other maternally expressed genes, Coco and Sox3, which can negatively modulate TGF-b signals (Bell et al., 2003; Zhang and Klymkowsky, 2007) .
In contrast to the maternal mechanism, the zygotic mechanism for ectodermal specification has remained less clear. In amphibian ectodermal development, classic explant studies have demonstrated the importance of zygotic mechanisms in the stagespecific loss of competence for mesodermal differentiation. Xenopus animal cap cells become committed to the ectodermal fate by the mid-gastrula stage and stop responding to mesodermal inducers such as TGF-b-family molecules that activate the Smad2/Smad4 pathway (Steinbach et al., 1997; Grimm and Gurdon, 2002) . This phenomenon cannot be easily explained by the involvement of maternal factors such as Ectodermin (Dupont et al., 2005) . A previous study showed that overexpression of constitutively active Notch can elongate the competence period of the animal cap for mesodermal induction (Coffman et al., 1993) . However, whether this mechanism plays a role in normal development remains unclear at present. In addition, although a few transcription factors expressed on the animal side have been recently shown to promote ectodermal differentiation, the molecular mechanisms behind these phenomena are still understood rather fragmentally (Mir et al., 2007; Snir et al., 2006) .
In this study, we performed a functional screen for ectodermspecific zygotic genes involved in this process and isolated a zygotic zinc (Zn)-finger nuclear factor, XFDL156, that actively suppresses mesodermal differentiation in the presumptive ectoderm.
RESULTS

Identification of a Zygotic Nuclear Factor that Inhibits Activin-Induced Mesodermal Differentiation
At the beginning of this study, we observed that microinjection of mRNA from stage 11.5 animal caps suppressed mesodermal differentiation induced by Activin (a TGF-b-family factor) more efficiently than did the injection of mRNA from stage 8.5 tissues (Figures S1A-S1D available online), suggesting that zygotic transcripts in the gastrula animal cap negatively modulate the cell's competence for mesodermal induction. We therefore constructed an expression cDNA library from stage 11.5 animal cap mRNA for a functional screen ( Figure 1A ). Two hundred pools of 96 plasmid clones were transcribed in vitro and injected into all the animal blastomeres of 8-cell embryos. Animal cap explants were prepared at stage 8.5, treated with Activin until stage 11, and analyzed for the expression of the early mesoderm marker gene Brachyury (Xbra; Smith, 1997) by quantitative RT-PCR (q-PCR). Twenty pools of mixed clones reproducibly suppressed Xbra expression (e.g., #105 in Figure 1B ) and were subjected to sib screening. Finally, we identified five individual clones with mesoderm-inhibiting activity ( Figure 1C ). They encoded XFDL156 (#105-F5), HMG-X (Kinoshita et al., 1994) , an E2 ubiquitin-conjugating enzyme (GenBank accession #BC088818), a presumptive RNA-binding protein related to SR-p38 (Liu and Harland, 2005) , and an SH3-containing protein (Tosoni et al., 2005) .
Among these, the function of the Zn-finger protein XFDL156 (XFDL, hereafter; containing multiple Krü ppel-type Zn fingers) has been unexplored (Bellefroid et al., 1997 ; Figure 1D ). Interestingly, XFDL expression is observed transiently ( Figure 1E ). XFDL first appeared at the late blastula stage diffusely in the animal cap region ( Figures 1F and 1G ). At the early gastrula stage, strong XFDL expression was detected widely in the presumptive ectoderm (Figures 1H and 1I ; both in the superficial and sensorial layers). XFDL expression at late gastrulation was limited to a rostral part of the neuroectoderm ( Figures 1E and 1J ). Immunostaining showed that XFDL was mainly located in the nuclei of animal cap cells ( Figure 1K ; Figures S1E-S1J for controls).
In the animal cap assay, overexpression of XFDL inhibited the Activin-induced expression of another early mesodermal gene, Mix.2 (Chen et al., 1996 (Chen et al., , 1997 , in addition to Xbra expression, suggesting that XFDL interferes with the differentiation of mesoderm from pluripotent cells ( Figures 1L-1Q ).
Specific Inhibition of Mesodermal Differentiation but Not of Neural or Endodermal Induction by XFDL Injection of XFDL did not reduce the expression of the endodermal markers Sox17a (Wardle and Smith, 2006) and Xenf (Nakatani et al., 2000) in Activin-treated animal caps, indicating that XFDL overexpression has little effect on early endodermal induction (Figures 2A and S2A) . XFDL inhibited the induction of neither Xnr-1 by Activin nor Siamois by Wnt8 in the animal cap assay (Wardle and Smith, 2006; Figures S2A and S2B) . XFDL injection did not suppress the induction of Sox2 by Chordin in the animal cap (Sasai et al., 1994; Mizuseki et al., 1998; Figure 2B) , showing that XFDL does not inhibit neural differentiation.
XFDL strongly suppressed Xbra (86%, n = 44; Figures 2C and 2D) and Mix.2 (78%, n = 45; Figures 2E and 2F) in the embryo. XFDL also decreased the expression of Chordin (dorsal mesoderm, 100%, n = 24; Figures 2G and 2H) and Vent1 (Gawantka et al., 1995; ventral mesoderm, 89%, n = 27; Figures 2I and 2J) , showing that mesodermal differentiation was generally impaired. In contrast, the in vivo expression of Sox17a (n = 56; Figures 2K and 2L), Sox2 (n = 30; Figures 2M and 2N) , and Xnr-3 (Smith et al., 1995; n = 22, Figures 2O and 2P) was largely unaffected. Interestingly, the expression of Foxi1a (Matsuo-Takasaki et al., 2005 ; a pan-ectodermal marker at this stage) and Foxi1e (Mir et al., 2007 ; another ectodermal marker) was expanded into the marginal zone by XFDL (Figures 2Q and 2R and not shown) . No substantial suppression of the mesodermal marker was observed when unrelated multiple Zn-finger factors, SalF and Tsh3 (Onai et al., 2004 (Onai et al., , 2007 , were overexpressed ( Figures 2S and  2T) . Thus, XFDL blocks not only in vitro mesodermal induction by exogenous Activin but also the endogenous program of in vivo mesodermal development in a germ-layer-specific manner.
Knockdown of XFDL Induces Aberrant Mesodermal Differentiation in the Presumptive Ectodermal Tissue
Injection of XFDL-MO experiments (see Figure S1K for controls) expanded Xbra expression toward the animal pole of the gastrula embryo (69%, n = 80; Figures 3A-3C ). This marked increase in Xbra expression was reversed by coinjection of XFDL (coding region only; no increase in 66%, n = 56; Figure 3D ). Strong induction was also observed for another pan-mesodermal marker, zygotic VegT ( Figures 3E and 3F) , suggesting that the knockdown of XFDL desuppresses the expression of mesodermal markers in the animal region.
In contrast, XFDL-MO injection reduced the Sox2 expression (94%, n = 34; Figures 3G and 3H) , suggesting that the expansion of mesodermal marker expression occurred at the expense of neural induction in the ectoderm. Unlike the mesodermal and neural markers, expression of the endodermal marker Sox17a was not affected (n = 25; Figures 3I and 3J) .
Explant experiments showed that XFDL-MO induced mesodermal marker expression (Xbra, VegT, and Mix.2) in the animal cap without Activin treatment ( Figure 3K ). In contrast, Chordininduced Sox2 expression in vitro was reduced by XFDL-MO in a dose-dependent manner ( Figure 3L ).
These findings suggest that XFDL is essential for the suppression of aberrant mesodermal differentiation in the presumptive ectodermal tissues.
XFDL Inhibits Mesodermal Gene Activation by p53 and Its Coactivator XFDL does not inhibit Activin from inducing endodermal differentiation (Figures 2A and S2A) , suggesting that the TGF-b signaling pathway per se is active in XFDL-overexpressing cells. Consistent with this idea, XFDL neither reduced the level of Smad2 proteins nor interfered with their phosphorylation ( Figure S2C ). In addition, injection of neither XFDL mRNA nor XFDL-MO substantially inhibited the nuclear accumulation of phosphorylated Smad2 upon Activin treatment (arrows in Figure S2D ).
Recent studies have revealed a critical role of p53 in mesodermal determination. p53 binds to the promoter of early mesodermal genes such as Mix.2 and cooperates with the Smad pathway (Cordenonsi et al., 2003; Takebayashi-Suzuki et al., 2003) . p53 is also implicated as a node point for the integration of the TGF-b and Fgf/MAPK signaling pathways (Cordenonsi et al., 2007) . However, relatively little is known about the restriction of the p53 function in the presumptive ectoderm.
Consistent with previous reports, p53 overexpression strongly expanded the expression of the mesodermal markers Xbra and Mix.2 toward the animal pole (47%, n = 62 for Xbra; 38%, n = 58 for Mix.2; Figures 4B and 4E) . Interestingly, coinjection of XFDL completely reversed these inductions (suppressed in 100%, n = 40 for each probe; Figures 4C and 4F ), indicating that XFDL counteracts the p53 activity. To further analyze this antagonism, we next performed animal cap assays. Mix.2 expression was strongly increased in the animal cap by coinjection of p53 and p300 (encoding a coactivator of p53; Gu et al., 1997; Lill et al., 1997) (Figure 4G ). This p53/p300-induced elevation of Mix.2 expression was inhibited by coinjection of XFDL in a dosedependent manner ( Figure 4G , lanes 3-5).
We next performed coinjection assays of XFDL-MO and p53-MO ( Figures 4H-4L ). As reported previously (Cordenonsi et al., 2003; Takebayashi-Suzuki et al., 2003) , p53-MO inhibited mesodermal differentiation in the embryo ( Figure 4J ). Coinjection of two MOs caused a phenotype indistinguishable from that caused by p53-MO alone ( Figure 4K ; n = 18, 100%). In addition, coinjection of p53-MO suppressed mesodermal marker induction by XFDL-MO in the animal cap ( Figure 4L ). These findings suggest that XFDL's function on mesodermal differentiation is largely dependent on p53 activity.
We next examined the effect of XFDL on p53/p300 activity in a luciferase assay using the Mix.2 promoter, which contains a p53-response element as well as an Activin-response element (ARE; Smad4/Fast1-binding site; Chen et al., 1996 Chen et al., , 1997 (Figures 4M and 4N) . XFDL caused a dose-dependent suppression of p53/p300 activity ( Figure 4O , lanes 3-5). Moreover, a similar suppression was observed even when the ARE was mutated in the Mix.2 promoter (Figures 4P and 4Q) . We next performed a luciferase assay using p53-luc, which contains a p53-specific promoter that consists of 14 repeats of a p53-binding element (derived from the Muscle Creatine Kinase promoter; Zambetti et al., 1992) and no ARE ( Figure 4R ). XFDL inhibited the p53/ p300-induced elevation of luciferase activity with this promoter ( Figure 4S , lanes 3-5), as was seen with the Mix.2 promoter (Figures 4O and 4Q) . In contrast, the Activin-induced activity of DE(4x)-luc (a pure Activin/Smad2-responding reporter; Watabe et al., 1995) was not affected by XFDL ( Figure 4T ). (S and T) Embryos injected with SalF (400 pg/cell; S) or Tsh3 (400 pg/cell; T) were analyzed at stage 10.5 by in situ hybridization using the Xbra probe.
We next tested whether XFDL interfered with p53 activity in a different biological assay, that is, apoptosis induction by p53 (Bode and Dong, 2004) . The p53-induced apoptosis was suppressed by coinjection of XFDL ( Figures S3B and S3C ). In contrast, a dominant-negative Fast1 (Fast1-EnR, which blocks the Smad/Fast1 pathway; Watanabe and Whitman, 1999 ; Figure S3D ) did not reverse the increase. Conversely, XFDL-MO increased the apoptosis in the animal cap ( Figure S3E ). This increased apoptosis was reversed by p53-MO but not by Fast1-EnR ( Figures S3F and S3G) . Thus, XFDL's effect on apoptosis appears to be related to p53 but not directly to the Smad/Fast1 pathway.
Taken together, these findings demonstrate that XFDL is capable of antagonizing p53 functions in early Xenopus tissues.
XFDL Depletion Prolongs the Competence Period for p53-Triggered Mesodermal Differentiation in the Animal Cap
We next examined mesodermal differentiation in response to temporally controlled p53 activity in the animal cap using a hormone-inducible construct of p53, GR-p53 (Takebayashi-Suzuki et al., 2003) . When GR-p53-injected animal caps were treated with dexamethazone (Dex) from stage 8.5, expression of the mesodermal markers Mix.2 and Bix3 (Trindade et al., 2003) was substantially increased (blue columns in Figures 4U and S5 , lane 3). Little increase, if any, in the expression of the mesodermal genes was seen when Dex treatment was started at stage 11 (equivalent) in GR-p53-injected animal caps (blue columns in Figures 4U and S5, lane 3) . Thus, the temporal window for high responsiveness to p53 activity terminates by the early gastrula stage equivalent in the animal cap. Interestingly, when XFDL-MO was coinjected, the responsiveness to Dex-induced p53 activity was maintained in the stage 11 animal cap (red columns in Figures 4U and S5, lane 6 ). These findings demonstrate that XFDL is required, at least in part, for the loss of cellular competence for p53-dependent mesodermal differentiation in the gastrula animal cap.
XFDL Directly Interacts with p53 and Reduces p53's Binding to Its Target DNA Site
We next studied whether XFDL and p53 physically interacted at the protein level. Immunoprecipitation analysis using HEK293 lysates ( Figure 5A ) showed that XFDL efficiently coprecipitated with p53 (lane 4; human). Moreover, immunoprecipitation of endogenous XFDL protein with HA-tagged Xenopus p53 was seen from animal cap extracts ( Figure 5B ). In addition, a strong physical association was seen between in vitro-translated XFDL protein and recombinant GST-hp53 protein, indicating that the two proteins directly interact ( Figure 5C , top row). In contrast, GSThp53 did not bind to the unrelated multiple-Zn-finger proteins SalF, Tsh3, and ROAZ ( Figure 5C , bottom three rows; Onai et al., 2004 Onai et al., , 2007 Tsai and Reed, 1999) . We next tested whether XFDL modulates the binding of p53 to its target sequence in the gastrula animal cap. In a gel shift assay, as previously reported (Luo et al., 2004) , the extract containing wild-type (WT) p53 (HA-tagged) induced only a faint band shift of the probe ( Figure 5D , lane 3) while constitutively active p53 (p53-2KQ; mutated at the regulatory domain; described later in Figure 6E ) efficiently bound to the probe ( Figure 5D , lane 1). Injection of XFDL-MO substantially facilitated the binding of WT p53 to the probe (lanes 4 and 5), suggesting that endogenous XFDL in the animal cap inhibits WT p53 from binding to its target sequence (see the supershift with the HA antibody in lane 6). Furthermore, in chromatin immunoprecipitation (ChIP) assays of genomic DNA using the endogenous Mix.2 promoter (Figure 5E ), the specific binding of p53 to this site was augmented by coinjection of XFDL-MO (compare lanes 3 and 4) and suppressed by XFDL overexpression (compare lanes 2 and 3). In contrast, no obvious change was observed for the Fast1 binding to the Mix.2 promoter ( Figure 5F ). These observations demonstrate that endogenous XFDL protein negatively regulates the target-specific DNA binding of p53 in presumptive ectodermal cells.
XFDL's Inhibitory Function on p53 Depends on the Carboxy-Terminal Regulatory Domain of p53
The carboxy-terminal (C-terminal) region of p53 functions as a regulatory domain (RD; Figure 6A ; Bode and Dong, 2004) . Indeed, p53 lacking the RD has a stronger mesoderm-inducing activity than does full-length p53 when injected into the animal cap ( Figure 6B , lanes 2 and 3; Cordenonsi et al., 2003; TakebayashiSuzuki et al., 2003) . We found that this domain of p53 is essential for the XFDL binding ( Figure 6C, lanes 1 and 2) . Furthermore, mesodermal differentiation caused by the mutant p53 lacking the RD (p53DRD) was not efficiently inhibited by coinjection of XFDL ( Figure 6D ). The RD contains multiple lysine residues that are acetylated by p300 ( Figure 6E ; Luo et al., 2004) . The mesoderm-inducing activity of p53 is impaired by an acetylation-resistant replacement of the lysine residues (K-R) in the RD, whereas it is enhanced by an acetylation-mimicking replacement (K-Q; Luo et al., 2004) (Figure 6F ). In an antiparallel manner, the binding of XFDL to p53 increased and decreased upon the K-R and K-Q replacements, respectively ( Figure 6G) . Importantly, the reduction of the mesoderm-inducing activity of p53 with the K-R replacements could be reversed by XFDL-MO ( Figure 6H , lanes 5 and 7). Taken together with the results shown in Figure 5D , these findings indicate that XFDL is involved in the reduction of p53 activity via the RD. It appears unlikely that XFDL actively interferes with p53 acetylation by p300 since the acetylation level of p53 in the animal cap is not strongly influenced by either XFDL or XFDL-MO injection ( Figure 6I) .
The p53 deletion analysis ( Figure S4A ) showed that the aminoterminal transactivation domain (TAD) was dispensable for the binding to XFDL ( Figure S4B , lane 6), while the rest (the C-terminal portion) of the protein structure was necessary for the physical interaction (lanes 4 and 5). This indicates that, although the RD plays a key role in the functional regulation by XFDL, a gross protein structure in the C-terminal portion of p53 is required for their strong physical interaction. In contrast, the short C-terminal portion of XFDL (containing only the last two Zn-finger motifs; Figure S4C ) was essential and sufficient for the binding to p53 ( Figure S4D , lane 5 and arrow in Figure S4E , lane 6).
Mammalian XFDL-Related Zn-Finger Proteins Inhibit p53 Activity
We next analyzed the specificity of XFDL among Zn-finger proteins (Looman et al., 2002) . SalF, Tsh3, (both Xenopus) and ROAZ (mouse), which are Zn-finger proteins unrelated to XFDL, did not bind to p53 in vitro ( Figure 5C ). Consistent with this, p53-induced luciferase activity was reduced by coexpression of XFDL but not by that of these unrelated Zn-finger factors ( Figure 7A ). In the mouse genome database, we found two multiple Zn-finger proteins (mZfp12 and mZfp74; Figure 7B ) that belong to the same subfamily as XFDL. They are strongly expressed in the early phases of neural differentiation of cultured mouse ES cells (Sox1 + neural precursors; Watanabe et al., 2005) but not in the maintenance culture (E-cadherin + uncommitted cells; Figure 7C and our unpublished data). Importantly, overexpression of each of them suppressed p53-luc activity as XFDL did ( Figure 7D , lanes 3-5). mZfp12 and mZfp74 bound to p53 protein ( Figure 7E , lanes 7 and 8), and overexpression of the two mouse factors inhibited mesodermal differentiation in the Xenopus embryo ( Figure 7F , two middle rows) and in the Activin-treated ( Figure 7G , lanes 3 and 4) and p53/p300-injected animal caps ( Figure 7H , lanes 3 and 4). These findings show that the XFDL-subfamily molecules, but not the unrelated Zn-finger proteins, have p53-binding and p53-inhibiting abilities.
DISCUSSION Active Restriction of p53 Function by a Zygotic Nuclear Factor Directs the Right Place and Time for Ectoderm-versus-Mesoderm Specification
In this study, we identified the nuclear Zn-finger factor XFDL as a zygotic suppressor of mesodermal differentiation in the presumptive ectoderm of Xenopus. The observation that XFDL conversely expands the expression of the pan-ectodermal marker Foxi1a into the marginal zone ( Figure 2R) indicates that XFDL plays a pivotal role in the binary fate decision. XFDL counteracts p53, which is essential for mesodermal differentiation (Cordenonsi et al., 2003 (Cordenonsi et al., , 2007 Takebayashi-Suzuki et al., 2003) . XFDL peaks at the onset of gastrulation ( Figure 1E ), when the animal cap starts to lose its competence for mesodermal differentiation. Importantly, when XFDL is blocked by XFDL-MO, the animal cap remains competent for p53-induced mesodermal differentiation even after the onset of gastrulation (Figure 4U) . This point casts a light on the unanswered question of whether the ubiquitous factor p53 (Hoever et al., 1994) plays an instructive (active) role or just a permissive role in the germlayer specification; the requirement of XFDL shown here clearly favors the former role. The present study has provided molecular evidence for a unique mode of p53 regulation: one antagonist of p53 that acts by directly repressing its DNA-binding activity, rather than promoting its degradation or modulating its activity via acetylation or phosphorylation (Brooks and Gu, 2003; Bode and Dong, 2004; Cordenonsi et al., 2007; Marechal et al., 1997) . In parallel to the XFDL system, the Smad pathway in the presumptive ectoderm is negatively modulated by the maternal factor Ectodermin (Dupont et al., 2005) . In the marginal zone (the presumptive mesoderm), local Nodal signals (Eimon and Harland, 2002) activate the Smad pathway. A recent report has suggested that Fgf signaling in the marginal zone (e.g., Fgf4) promotes p53 phosphorylation via the MAPK-CK1 pathway and thereby enhances the cooperative mesodermal differentiation by p53 and Smad in the marginal zone (Cordenonsi et al., 2007) . The combination of these regulations (p53, XFDL, Smad, and Fgf) seems to constitute a bi-stable relationship for the germ-layer specification: a dual-negative status (p53-off, Smad-off) in the ectoderm and a dual-positive one (p53-on, Smad-on) in the marginal zone.
In fact, several other mechanisms (both maternal and zygotic) have been implicated in the negative regulation of the Smad signals in the animal cap, including Smurf, Smad6/7, Coco, and Sox3 (Bell et al., 2003; Nakayama et al., 2001; Zhang et al., 2001; Zhang and Klymkowsky, 2007) . Probably because of these, XFDL-MO alone does not clearly elongate the competence period of the animal cap for mesodermal induction by Activin ( Figure S6A ; the same is the case for the induction by Fgf; Figure S6B ). Xenopus embryos were injected with the indicated mRNAs (400 pg/cell each) and animal caps were analyzed as in Figure 2A . (H) q-PCR analysis for Mix.2 expression in the animal cap. mRNAs of mammalian XFDL-related genes were coinjected with hp53 (50 pg/cell) and hp300 (200 pg/cell) (lanes 2-5). Analysis was performed as in Figure 4G .
XFDL expression in the animal cap is not downregulated by Activin (our unpublished data), suggesting that the ectodermspecific expression of XFDL is not simply due to the lack of TGF-b signals in the animal cap. Two ectoderm-specific transcription factors, Foxi1e and XLPOU91 (Mir et al., 2007; Snir, et al., 2006 ; neither binds to p53; our unpublished data), do not seem to lie upstream of XFDL expression either; the injection of neither Foxi1e nor XLPOU91 upregulates XFDL expression (our unpublished data; in addition, their transcripts start to be expressed in the ectoderm clearly after the onset of XFDL expression).
Differential Effects of XFDL on Fast-Independent and -Dependent AREs Previous studies have indicated that ''ARE'' can be generally classified into the Fast-independent (reviewed in Wardle and Smith, 2006) and Fast-dependent (Watanabe and Whitman, 1999) types. The distal-element ARE activity of the goosecoid promoter is a typical pure reporter of Smad2 activity and does not depend on Fast, whereas the Mix.2 ARE belongs to the latter type. We found (rather unexpectedly) that, unlike the distal-element ARE activity of the goosecoid promoter, the activity of the ARE reporter derived from the Mix.2 promoter (pARE(Mix.2)-luc; Chen et al., 1996 Chen et al., , 1997 Cordenonsi et al., 2003 ; Figure S7A ) is inhibited by XFDL, although this pARE(Mix.2)-luc reporter neither responds to p53 activity nor contains any p53-binding site (Figures S7B-S7D ).
We therefore examined the effect of XFDL on Fast gene expression ( Figure S8 ) and found that XFDL substantially decreases the expression of Fast1 and Fast3 in the stage 11 animal cap ( Figures S8J, S8M, and S8O ). This suppression of Fast genes by XFDL seems to explain, at least in part, why XFDL inhibits pARE(Mix.2)-luc activity but not DE(4x)-luc activity. This idea of the secondary (not primary) effect of XFDL is strongly supported by the observations that coinjection of Fast1 (which keeps Fast1 expression high) makes pARE(Mix.2)-luc activity insensitive to XFDL ( Figure S7F ; similar effects are seen for the Mix.2 reporter with point mutations in the p53-binding site; Figure S7H) . In contrast, Fast1 coinjection does not affect XFDL's inhibition of the activity of WT Mix.2-luc, which involves both an ARE and a p53-binding element ( Figure S7E ).
Taken together with the DE(4x)-luc data ( Figure 4T ), these findings demonstrate that the p53-binding element plays a primary role in the direct inhibition of the Mix.2 promoter by XFDL.
XFDL-Related Factors Share Similar Functions
The vertebrate genome contains a large number of diverse multiple-Zn-finger proteins. Unlike multiple-Zn-finger proteins diverse from XFDL, the XFDL-related mouse Zn-finger proteins (mZfp12 and 74; expressed during early neuroectodermal differentiation of mouse ES cells) bind to p53 and suppress p53-luc activity in the cotransfection assay using mammalian cells (Figures 7D and 7E) . Moreover, when overexpressed, they can inhibit mesodermal differentiation in the Xenopus embryo and in the animal cap treated with Activin or injected with p53/p300 ( Figures 7F-7H ). These findings indicate that the p53-inhibiting function is shared by XFDL-related Zn-finger proteins but not necessarily by multiple-Zn-finger proteins in general.
Whether the mammalian germ-layer specification involves a mechanism similar to that in Xenopus is an important and challenging research topic. Given that a recent report has suggested an essential role of p53 in an early phase of mouse ES cell differentiation (Lin et al., 2005) , a conserved mechanism of vertebrate ectodermal specification involving Zn-finger proteins and p53 is an attractive hypothesis, which should be functionally tested by various approaches including gene targeting.
EXPERIMENTAL PROCEDURES
Functional Screening A cDNA plasmid library was constructed from stage 11.5 animal caps using the pBluescript SK (À) vector. Each colony with an insert was cultured individually in the well of a 96-well plate. For the initial screen, synthetic RNA was prepared from each pool of mixed 96 clones by the mMessage mMachine kit (Ambion). Ten nanograms of mRNA per pool was injected into all the animal blastomeres at the 8-cell stage. Animal caps were excised at the mid-blastula stage (stage 8.5), incubated until stage 11 (equivalent) with 5 ng/ml of Activin, harvested, and analyzed for Xbra expression by q-PCR (ABI, model 7500; normalized by ODC/ornithine decarboxylase expression). Twenty pools showed inhibitory effects (down to <50%) and were subjected to sib screening.
Embryonic Manipulation, Expression Analysis, and Cell Culture 4-or 8-cell embryos were injected with synthetic mRNAs using a fine glass capillary and a pneumonic pressure injector (Narishige). Excised animal caps were cultured in 13 LCMR supplemented with 0.2% BSA until given stages. Whole-mount in situ hybridization analysis was performed with DIG-labeled antisense RNA probes. For immunohistochemistry, animal caps were sectioned at 10 mm increments. RT-PCR and western blot analyses were performed as described . For luciferase assays, the promoter regions of Mix.2 and Gsc were amplified by PCR and inserted into the pGL3 enhancer vector (Promega) (pMix.2-luc, pMix.2-AREmut-luc, and DE(4x)-luc; Cordenonsi et al., 2003; Chen et al., 1996; Watabe et al., 1995) . p53-luc (containing 14 repeats of a p53-binding element of the Muscle Creatin Kinase promoter) was purchased from Stratagene. The luciferase activity of each sample was normalized by the activity of coinjected (or cotranfected) phRL-null (Promega). Injection experiments were performed at the 4-cell stage for wholemount analyses and at the 8-cell stage for animal cap assays. GFP was used as the control neutral RNA. Primer sets for RT-PCR ( Figure 5E ) and q-PCR are shown in Table S1 . The expression of each gene was normalized to the FGFR1 expression ( Figure 1E ) or ODC expression (the other experiments). The design of MOs is described in Supplemental Experimental Procedures. Unless otherwise stated, human p53 (Bode and Dong, 2004) and human p300 (Bellefroid et al., 1997) were used in this study because of the availability of good specific antibodies (for instance, those for acetylated p53). Xenopus p53 and human p53 exhibit similar mesoderm-inducing activities ( Figure S7I ), which are inhibited by XFDL (not shown). Transfection experiments using H-1299 (lacking active p53; Luo et al., 2004; Cordenonsi et al., 2007) and HEK293 cells were performed with pCS2-based expression plasmids. Cells were harvested 24 hr after transfection and lysed with TNEB buffer (150 mM NaCl, 5 mM MgCl 2 , 10 mM Tris-HCl [pH 7.8], 1 mM EDTA, 0.5% NP-40) with protease inhibitors. To raise anti-XFDL156 antiserum, bacterially expressed recombinant XFDL156 (amino acid residues 1-250; GST-fused) was used to immunize rats. FACS sorting of undifferentiated and differentiating mouse ES cells (Sox1-GFP ES cells; a kind gift of Dr. Austin Smith) was performed as described previously (Watanabe et al., 2005) .
Immunoprecipitation, Pull-down, ChIP, and EMSA Immunoprecipitation assays were performed with protein G Sepharose (GE Healthcare) and subsequently analyzed by western blot. Antibodies used in this study were anti-FLAG, anti-HA (Sigma), anti-Smad2 (Cell Signaling Technology), anti-Phospho-Smad2 (Calbiochem), anti-Acetyl-p53 (Upstate Biotechnology), and anti-p53 (clone X-77; Santa Cruz Biotechnology). Pulldown experiments using glutathione Sepharose were performed as described previously (Cordenonsi et al., 2003) . Successful production and purification of GST-fused proteins were confirmed by SDS-PAGE and CBB staining (data not shown). In vitro protein synthesis was performed by using the TNT transcription/translation kit (Promega) in the presence of [
35 S]-Methionine (GE Healthcare). ChIP (Stewart et al., 2006) and EMSA (Germain et al., 2000; Wolkowicz et al., 1995 ) assays were performed as described.
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